吉西他滨联合卡铂治疗老年晚期非小细胞肺癌的临床疗效

Clinical Obsorvation of Gemcitabme and Carboplatin in Treating Older Advanced Non-small-cell Lung Cancer

目的:观察吉西他滨(GEM)联合卡铂化疗方案治疗老年晚期非小细胞肺癌患者的临床疗效及不良反应。方法:对住院治疗的25例老年晚期非小细胞肺癌患者采用GEM联合CBD化疗方案,GEM1000mg/m2,第1、8天,卡铂350mg/m2第1天。每4周重复,至少治疗两个周期,按标准评价疗效和毒副反应。结果:可评价患者25例,有效率52%,中位生存期7.3个月,1年生存率为34%。主要毒性反应为骨髓抑制、消化道反应,多数Ⅰ°～Ⅲ°反应。结论:GEM联合卡铂方案治疗老年晚期非小细胞肺癌临床疗效好,毒副反应可耐受。

Objective To observe The Clinical efficacy and side reaction of gemcitabine（GEM） and carboplatin（CBD） regimen in elder patients with advanced non-small-cell lung cancer（NSCLC）.Methods Twenty-five elder patients with unresectable NSCLC were enrolled for this study Gemcitabine were administered 1000mg/m^2 on day 1,8 and carboplatin 350mg/m^2 on day 1 intravenously every 4 weeks and with at least 2 cycles.Results In the 25 evaluable cases the response rate was 52%,Median survival time was 7.3months and 1 year survival rate was 34%.The main toxicity was myelosuppression,gastrointestinal tract reaction.The most were grade 1 or 3. Conclusion The schedule of gemcitabine and carbiplatin on elder advanced NSCLC has good clinical efficacy abd tolerability.